Clinical trials: Alcoholic Liver Disease
Nonalcoholic Steatohepatitis, Fibrosis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
- Trial name
- NASH (NCT05011305)
- Testing
- Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg
- Where
- 129 sites in United States, Argentina and 2 more
- Volunteers
- 189 people
- Sponsor
- Zydus Therapeutics Inc.
Non-Alcoholic Fatty Liver Disease, Glucagon Resistance
The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover
Many patients with type 2 diabetes exhibit elevated plasma concentrations of the glucose-mobilising pancreatic hormone glucagon; i.e. hyperglucagonaemia.
- Trial name
- NCT04859322
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Malte Palm Suppli, MD
Non-alcoholic Fatty Liver Disease
Dietary Allowance of Methyl Donor Nutrients to Minimize Risks of Non-alcoholic Fatty Liver Progression
Investigate the methyl donors requirement of NAFLD patients to correct the malnutrition, lipid-toxicity, microbiota dysfunction, and metabolomics biomarkers.
- Trial name
- NCT05291104
- Testing
- Folic acid, choline chloride
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Fu Jen Catholic University Hospital
NAFLD
Healthy Eating Through Reduction Of Excess Sugar
The purpose of the study is to determine the effect of dietary sugar reduction in obese children and examine whether there are differential effects based on genotype of a single amino acid substitution in the PNPLA3 gene that is…
- Trial name
- HEROES (NCT02948647)
- Testing
- Standard of care plus sugar-reduction education
- Where
- 2 sites in United States
- Volunteers
- 113 people
- Sponsor
- University of Southern California
Dietary Intake, NAFLD
Dietary Determinants in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
Patients with NAFLD and matched controls will be asked about their demographic status, and their previous year dietary intakes using a validated FFQ.
- Trial name
- NCT02649049
- Testing
- there is no intervention
- Where
- Iran
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Nutrition and Food Technology Institute
Metabolic Dysfunction-Associated Steatotic Liver Disease
Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD) Objective: This study aims to assess…
- Trial name
- DEFIB-MASLD (NCT06920316)
- Testing
- Gro Health digital application
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- St. George's Hospital, London
Non-alcoholic Fatty Liver Disease (NAFLD)
Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease
The goal of this open-label, non-randomized, prospective study is to compare Velacur and MRE in all sexes, 18-80 years old with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT05908006
- Testing
- Velacur
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- GI Alliance
Nonalcoholic Steatohepatitis
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis
This is a multi-center, randomized, placebo-controlled, double-blind, dose-selection, multiple dose administration study comprising three groups, with up to 40 patients in each active treatment and placebo group.
- Trial name
- NCT01466894
- Testing
- IMM 124-E
- Sponsor
- Immuron Ltd.
Non Alcoholic Fatty Liver Disease
Effects of Turkish Coffee and Green Tea in Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a common liver condition associated with metabolic disorders and lifestyle factors.
- Trial name
- NCT07768956
- Testing
- green tea, Turkish Coffee, mediterranean diet
- Where
- Turkey (Türkiye)
- Volunteers
- 47 people
- Sponsor
- Okan University
NASH - Nonalcoholic Steatohepatitis, Liver Fibroses
Liquid Biopsy for NASH and Liver Fibrosis
Nonalcoholic fatty liver disease (NAFLD) has evolved to represent the most common cause of chronic liver disease globally. Today, NAFLD is a leading indication for liver transplantation and a major etiology for hepatocellular…
- Trial name
- LIBRA (NCT04677101)
- Testing
- Liver Biopsy
- Where
- 2 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Catholic University of the Sacred Heart
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity.
- Trial name
- AdipoDROMExpo (NCT07330830)
- Where
- 3 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Non-alcoholic Fatty Liver Disease (NAFLD)
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT01811472
- Testing
- LCQ908
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Alcohol-Related Disorders
AlcoChange: An Open Label Pilot Study of Smartphone Monitoring for Alcoholic Liver Disease
Alcohol contributes to over 5% of deaths worldwide, and death rates from alcohol-related liver disease (ARLD) in the UK continue to rise sharply.
- Trial name
- NCT03474328
- Testing
- AlcoChange
- Volunteers
- 60 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Fatty Liver
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The study is designed to investigate the relationship between insulin resistance and non-alcoholic fatty liver disease (NAFLD) and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining…
- Trial name
- NCT01289639
- Testing
- fenofibrate, pioglitazone
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
Antidiabetic Effects on Intrahepatic Fat
This was a 24-week single-center, open-label, parallel controlled group comparing gliclazide, liraglutide, and metformin effects on diabetes with nonalcoholic fatty liver disease.
- Trial name
- NCT03068065
- Testing
- Liraglutide, Metformin, Gliclazide
- Where
- China
- Volunteers
- 87 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hepatic Encephalopathy, Cirrhosis
Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome
Investigating the impact of hepatic encephalopathy on default mode networks within the brain to provide more clues with understanding the physiology of consciousness and predicting the reversibility of comatose states.
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
- Trial name
- NCT02083367
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OSF Healthcare System
Autoimmune Hepatitis, Non-Alcoholic Fatty Liver Disease
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach
This is a two-arm, prospective, controlled observational pilot clinical study aimed at characterizing the lipidomic profile and extracellular vesicles (EVs) of patients with autoimmune hepatitis (AIH) compared to patients with…
- Trial name
- AIH-LIPID (NCT07644936)
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Overweight or Obesity
Soy Peptide, Conjugated Linoleic Acid, Overweight or Obese, Body Composition
Soybean peptides are a mixture of active peptides obtained from the hydrolysis of soybean protein, which have biological activities such as antioxidant, blood pressure lowering, anti-fatigue and lipid lowering, etc.
- Trial name
- NCT04728399
- Testing
- Experimental group, Control group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fangfang Zeng
Non-alcoholic Fatty Liver Disease NAFLD
Assessment of Tolerability of Specialized Food Products Made Out of Vegetable Protein and Their Influence on Lipid Profile in Patients With Non-alcoholic Fatty Liver Disease
To this single-centre randomized controlled comparative study it is planned to enroll 50 patients with non-alcoholic fatty liver disease. All these subjects will receive standard isocaloric diet for 14 days.
- Trial name
- NCT06727279
- Testing
- Specialized food - Plant-Based Meat Analog, standard isocalorie diet
- Volunteers
- 50 people
- Sponsor
- Federal State Budgetary Scientific Institution
Non-Alcoholic Fatty Liver Disease, Dietary Modification
Chia Supplementation and Non Alcoholic Fatty Liver Disease
Parallel to epidemic obesity, non-alcoholic fatty liver disease (NAFLD) prevalence has markedly increased during the last years, and recent data point out that one of three adults courses with this disease.
- Trial name
- NCT03942822
- Testing
- Milled chia seeds
- Volunteers
- 40 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.